Volume 281, Issue 1 pp. 154-168
INVITED REVIEW
Open Access

Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family

Corinne Cayrol

Corresponding Author

Corinne Cayrol

Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France

Correspondence

Dr. Jean-Philippe Girard (or) Dr Corinne Cayrol, IPBS-CNRS-Université de Toulouse, Toulouse, France.

Emails: [email protected] (or) [email protected]

Search for more papers by this author
Jean-Philippe Girard

Corresponding Author

Jean-Philippe Girard

Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France

Correspondence

Dr. Jean-Philippe Girard (or) Dr Corinne Cayrol, IPBS-CNRS-Université de Toulouse, Toulouse, France.

Emails: [email protected] (or) [email protected]

Search for more papers by this author
First published: 16 December 2017
Citations: 659

Summary

Interleukin-33 (IL-33) is a tissue-derived nuclear cytokine from the IL-1 family abundantly expressed in endothelial cells, epithelial cells and fibroblast-like cells, both during homeostasis and inflammation. It functions as an alarm signal (alarmin) released upon cell injury or tissue damage to alert immune cells expressing the ST2 receptor (IL-1RL1). The major targets of IL-33 in vivo are tissue-resident immune cells such as mast cells, group 2 innate lymphoid cells (ILC2s) and regulatory T cells (Tregs). Other cellular targets include T helper 2 (Th2) cells, eosinophils, basophils, dendritic cells, Th1 cells, CD8+ T cells, NK cells, iNKT cells, B cells, neutrophils and macrophages. IL-33 is thus emerging as a crucial immune modulator with pleiotropic activities in type-2, type-1 and regulatory immune responses, and important roles in allergic, fibrotic, infectious, and chronic inflammatory diseases. The critical function of IL-33/ST2 signaling in allergic inflammation is illustrated by the fact that IL33 and IL1RL1 are among the most highly replicated susceptibility loci for asthma. In this review, we highlight 15 years of discoveries on IL-33 protein, including its molecular characteristics, nuclear localization, bioactive forms, cellular sources, mechanisms of release and regulation by proteases. Importantly, we emphasize data that have been validated using IL-33-deficient cells.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.